Epidermal growth factor receptor (EGFR) is a target in many cancers, but EGFR inhibitors have displayed little utility in treating glioblastoma (GBM) due to limited blood-brain barrier (BBB) penetration.
Researchers from Abl Bio Inc. recently presented preclinical data for the novel asymmetrical CLL1/CD3 bispecific antibody ABL-602, being developed for the treatment of acute myeloid leukemia (AML).
Sex differences at the cellular level could explain why men respond less well to glioblastoma (GBM) treatments, according to a study led by the Washington University School of Medicine in St. Louis (WUSTL). The researchers found that male and female GBM tumor cells had different metabolic needs. GBM cells from male surgical samples absorbed more glutamine and had different nutritional preferences for amino acids.
Scientists from the University of Queensland have created a new antibiotic that can neutralize various gram-positive bacteria in mice, including major threats such as methicillin-resistant Staphylococcus aureus (MRSA). In a recent study, published in the Sept. 14, 2022, issue of Science Translational Medicine, the new compound outperformed the approved antibiotic vancomycin, and destroyed tough-to-eradicate bacterial biofilms while prompting a low rate of resistance.
Bayer AG has discovered P2X purinoceptor 3 (P2RX3) antagonists reported to be useful for the treatment of overactive bladder, chronic cough, endometriosis, cancer, heart failure, irritable bowel syndrome with diarrhea, pain and sleep apnea, among others.
University of Chicago has described estrogen receptor (ER)-α antagonists reported to be useful for the treatment of cancer, fibroids, uterine (myoma), hormone replacement therapy, menopause, obesity, osteoporosis and atrophic vulvovaginitis.
The Royal Veterinary College has presented drug conjugates comprising hyaluronan (HA) synthesis inhibitors covalently bonded to betaine reported to be useful for the treatment of chondrosarcoma and osteoarthritis.
Gentibio Inc. has announced preclinical data relating to the company's platform technology, demonstrating technical progress to engineer regulatory T cells (Tregs) for the prevention and treatment of autoimmune diseases.
RSS
